Prior to joining BiondVax as CEO in 2021, Mr. Amir Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines headquarters in Belgium. Previously, he served as Senior Director Global GSK Vaccines Supply Chain.
At Novartis Vaccines, he held various leadership roles of increasing responsibility in its Global Vaccines Supply Chain Management organization located in Holly Springs, NC, USA.
Mr. Reichman’s academic work contributed to the founding of NeuroDerm Ltd., an Israeli company focused on transdermal drug delivery systems that was acquired by Mitsubishi Tanabe Pharma in 2017 for $1.1B. He was NeuroDerm’s first employee and served as the company’s Chief Engineer and Senior Scientist until his departure in 2009.
Mr. Reichman earned an M.Sc. in Biotechnology Engineering from Ben-Gurion University of the Negev in Israel, and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania, USA.
At Novartis Vaccines, he held various leadership roles of increasing responsibility in its Global Vaccines Supply Chain Management organization located in Holly Springs, NC, USA.
Mr. Reichman’s academic work contributed to the founding of NeuroDerm Ltd., an Israeli company focused on transdermal drug delivery systems that was acquired by Mitsubishi Tanabe Pharma in 2017 for $1.1B. He was NeuroDerm’s first employee and served as the company’s Chief Engineer and Senior Scientist until his departure in 2009.
Mr. Reichman earned an M.Sc. in Biotechnology Engineering from Ben-Gurion University of the Negev in Israel, and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania, USA.
Speaking In
4:15 PM - 4:30 PM (EST)
Monday, February 6
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing,…
Winter Garden
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
